Does Anavar Burn Fat? The Trial That Measured It
Does Anavar Burn Fat? The Trial That Measured It
Does Anavar burn fat is one of the few questions about oxandrolone that a trial answers directly. Schroeder and colleagues (Journal of Clinical Endocrinology and Metabolism, 2004) gave 32 men aged 60 to 87 either 20 mg of oxandrolone a day or placebo for 12 weeks, with no diet or training programme, and measured fat by DEXA and MRI. Total fat fell by 1.8 kg, trunk fat by 1.2 kg and limb fat by 0.6 kg, all significantly more than placebo. On MRI, visceral abdominal fat fell by 20.9 cm², subcutaneous abdominal fat by 10.7 cm², and the visceral-to-subcutaneous ratio dropped. A marker of insulin sensitivity improved, and the men who lost the most fat were those whose baseline testosterone was lowest (300 ng/dL or less).
So the answer is yes, measurably, at a clinical dose, in men who changed nothing else. The rest of this page is about the size of the effect, where the fat comes from, what happened after the drug was stopped, and why the number in a mirror after a six-week cut is mostly the diet.
Key takeaway: 20 mg a day for 12 weeks removed about 1.8 kg of fat, with the largest share from the trunk and a measurable drop in visceral fat, in men who did not diet or train. Twelve weeks after stopping, 83% of the fat loss was still there. On a cut, oxandrolone's bigger contribution is keeping muscle while the deficit removes the fat.
Where the Fat Went
The pattern matters more than the total. The loss was concentrated in the trunk and, within it, in visceral fat, the deposit around the organs that drives metabolic risk. Visceral adipose tissue fell by 20.9 cm² on cross-sectional MRI, a larger relative change than subcutaneous fat, and the ratio of visceral to subcutaneous fat fell from 0.57 to 0.49. That is consistent with how androgens act on fat: they reduce fat storage in abdominal depots and increase fat release from them, and men with low testosterone, who carry more visceral fat, responded most. The improvement in the insulin-sensitivity index moved in the same direction.
Fat changes on 20 mg oxandrolone for 12 weeks (Schroeder 2004, JCEM, 32 men aged 60 to 87)
Total fat (DEXA)
−1.8 kg
Significantly greater than placebo
Trunk fat
−1.2 kg
Two thirds of the loss
Limb fat
−0.6 kg
Visceral abdominal fat (MRI)
−20.9 cm²
Largest relative change
Subcutaneous abdominal fat (MRI)
−10.7 cm²
Thigh subcutaneous fat
−8.3 cm² proximal
Insulin-sensitivity index
Improved
Correlated with fat loss
12 weeks after stopping
83% of fat loss retained
Muscle and strength gains had returned to baseline
What Happened After Stopping
The companion paper (Schroeder, Journal of Applied Physiology, 2004) followed the same men 12 weeks after the drug was withdrawn. The lean mass and strength they had gained were no longer different from baseline, but most of the fat loss remained: 83% of it. The muscle effect of oxandrolone is rented; the fat effect, at least over that window, was closer to owned. Users describe the same asymmetry after a cycle: the hardness and pump fade within a week or two, the leaner waist stays as long as the diet does. The timeline of both is in Anavar results week by week.
The Bigger Effect on a Cut
In a trial with no diet, the drug did all the work and removed 1.8 kg in 12 weeks. On a cut the arithmetic changes: a 500-calorie daily deficit removes roughly that much fat every three to four weeks on its own, and the question becomes what oxandrolone adds. Its main contribution is anti-catabolic: in the same trial it added 3.0 kg of lean mass without training, and in a deficit that effect shows up as muscle that is kept rather than lost. Users on 40 to 50 mg in a deficit describe holding or adding strength while losing fat, and a harder, drier look because the drug does not aromatise and holds no water. The fat itself comes off at the rate the deficit sets; the oxandrolone decides how much of what remains is muscle. The cycle guide sets out the diet that makes this work.
What It Does Not Do
Oxandrolone is not a fat burner in the sense of a stimulant or a thermogenic. It does not raise heart rate or temperature, it does not suppress appetite, and no trial shows it increases daily energy expenditure in a way that would let someone eat at maintenance and lose fat quickly. The visceral-fat effect is real and metabolically useful, but 1.8 kg in 12 weeks is the measured scale of it at a clinical dose. Claims of ten pounds of fat gone from the compound alone are describing a diet.
Women report the same pattern at 5 to 10 mg: a leaner midsection and held muscle in a deficit, covered in Anavar for women. The costs that come with the fat loss, lipids, liver enzymes and suppression, are set out in is Anavar safe.
Yes, measurably. In the 2004 trial at 20 mg, trunk fat fell 1.2 kg and visceral abdominal fat fell 20.9 cm² on MRI in 12 weeks, the largest relative change of any fat depot, with the greatest losses in men with low baseline testosterone.
About 1.8 kg of total fat in 12 weeks at 20 mg a day in men who did not diet or train. On a cut the deficit removes the fat; oxandrolone's larger effect is holding muscle while it does.
It did in the trial: the men did not train and still lost 1.8 kg of fat and gained 3.0 kg of lean mass. The effect is modest and the muscle gain disappeared after stopping; the fat loss mostly stayed.
No. It is an anabolic steroid with a measurable fat-reducing effect, not a stimulant or thermogenic. It does not raise energy expenditure or suppress appetite.
Twelve weeks after the drug was stopped, 83% of the fat loss remained in the trial, while the muscle and strength gains had returned to baseline. Whether it stays longer depends on diet.
This article is for educational and harm-reduction purposes only and is not medical advice. Oxandrolone is a prescription-only or controlled substance in most countries; anyone considering it should consult a licensed physician.
Anavar.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.
Ryan Caldwell
Author
Comments (0)
Be the first to comment on this article.
